Compare Mitsubishi UFJ Financial Group Inc. Common Stock (MUFG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mitsubishi UFJ Financial Group Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? Mitsubishi UFJ Financial Group Inc. Common Stock trades at $21.65 (market cap $252.11B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Mitsubishi UFJ Financial Group Inc. Common Stock is far larger — about 69.6× Organon & Co. Common Stock's market cap, and Mitsubishi UFJ Financial Group Inc. Common Stock pays the higher dividend (2.41%). Which is the better fit depends on your goals — on Pluang, investors hold Mitsubishi UFJ Financial Group Inc. Common Stock for 2 Days and Organon & Co. Common Stock for 0 Days on average.
| MUFG | OGN | |
|---|---|---|
Market Cap | $252.11B | $3.62B |
Volume | 3,452,336 | 2,892,999 |
Sector | Financials | Health |
52-Week High | $24.13 | $13.81 |
52-Week Low | $14.77 | $5.70 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $29.18T | $11.04B |
Dividend Yield | 2.41% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MUFG trades at $22.40, up 0.22% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.45 exceeding the $0.35 estimate. Fundamentals show robust profitability with a 34.22% net income margin and 12.6% ROE, while valuation ratios like a P/E of 14.99 appear reasonable. Recent news highlights a partnership with SkyDrive for eVTOL feasibility studies and positive analyst momentum coverage.
The outlook is supported by earnings momentum and a 100% buy rating from analysts, but risks include a high debt-to-asset ratio of 5.81 and significant negative cash flow trends. Investor sentiment is optimistic due to strong quarterly results and institutional interest, though technical weakness and macroeconomic sensitivity pose near-term challenges.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mitsubishi UFJ Financial Group Inc. Common Stock
Mitsubishi UFJ Financial Group is a Japanese financial services company providing banking, lending, securities, and asset management services. Its businesses serve individuals, companies, and institutions worldwide.
Read more on MUFG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
